Compare GSK plc (GSK) vs Manulife Financial Corporation (MFC) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Manulife Financial (MFC) trades at $41.69, up 0.97% on the day and near its 52-week high, reflecting strong technical momentum. The company reported mixed Q1 2026 earnings but has beaten estimates in two of the last three quarters, with revenue growing to $53.01B in 2025. Analyst consensus is bullish with 8 Buy ratings and no Sell recommendations, supported by a solid 12.07% net income margin and 13.14% ROE. Recent news highlights AI advancements and a strong Asia business, though regulatory scrutiny on certain products presents a watch item.

The outlook for MFC is positive, driven by earnings growth in Asia, strategic AI investments, and a robust capital position. Key opportunities include expansion in wealth management and continued dividend returns. Primary risks involve regulatory pressures in Hong Kong, volatility in global wealth segments, and potential margin compression from competitive and macroeconomic forces.